Related Experiment Video
Updated: May 21, 2026
08:57
Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models
Published on: May 17, 2024
A rare breast tumor: solid neuroendocrine carcinoma.
Annali Italiani Di Chirurgia
|June 8, 2012
Summary
Solid neuroendocrine carcinoma of the breast (NECB) is rare. This case highlights the aggressive nature of inflammatory NECB, emphasizing the need for novel therapeutic strategies like VP16-cisplatin to improve patient outcomes.
Area of Science:
- Oncology
- Pathology
Background:
- Solid neuroendocrine carcinoma of the breast (NECB) is an exceptionally rare malignancy.
- This study presents a case of inflammatory primary solid NECB, reviewing its epidemiology, clinical presentation, diagnosis, pathology, treatment, and prognosis.
Observation:
- A 63-year-old woman presented with a 6.5 cm inflammatory primary solid NECB in her right breast.
- The tumor showed positive staining for neuroendocrine markers chromogranin A and synaptophysin.
- Metastasis was confirmed in 19 out of 27 axillary lymph nodes.
Findings:
- The patient received neoadjuvant chemotherapy, radical mastectomy, and axillary lymph node dissection.
- Despite initial treatment, local recurrence and metastatic progression occurred one month post-surgery.
- The patient is currently alive 24 months after diagnosis following chemotherapy and hormone therapy.
Implications:
- Solid NECB is characterized by a high propensity for local and distant recurrence, lacking a standardized treatment protocol.
- This case underscores the importance of exploring novel therapeutic regimens, such as VP16-cisplatin, which showed partial efficacy.
- Further research into innovative treatments is crucial for improving the prognosis of this rare breast cancer subtype.